Ozempic,
an originally indicated medication for the treatment of
Type 2 diabetes, has become one of the most demanded drugs
In Spain.According to statista data published in May 2025,
laboratories invoiced almost 485 million euros in 2024 for the sale
of Ozempic and its analogues, a figure 21 times higher than the registered
In 2019. This exponential boom in its consumption is closely
relating to its growing useas treatment for obesityAnd it is aSupply problem for diabetic patients who need it.

In this context, Health launched an order
Ministerial last Tuesday, July 8, 2025. Although in the document
They did not cite any concrete drugs, they did spoke of «recurringSupply problemsof certain medications for its use in indications not
authorized or financed ”, something that is happening with Ozempic and its
AnaloguesThe Spanish Ministry proposed "the implementation of a
double price system for these medications »to preserve your
Availability in the indications financed by the government of
Spain.

The double price will be temporary

Health points out that the double price will be a temporary measure that is
It will take on the medications that are determined.If the proposal continues
Go ahead, we will still have to determine which drugs will be affected,
Although Ozempic starts as one of the main candidates.The
medications that are included in the

list will be those who are part ofThe pharmaceutical provision of the National Health System (SNS), that may have a "significant" use for unsigned indications or outside those approved in their technical file.

For continuing with Ozempic's example, pharmacies
They can sell it as a medicine for other non -indicated purposes, but
They must make their price more expensive.The cost must be similar to that of others
Drugs used against obesity not financed, such asWegovyThe price of this other medicine in Spain ranges from € 180
for the initial doses and the € 292 per month for those of
Maintenance, according to data contrasted in July 2025.

This double price will be put only when it has been prescribed to
an out of your indication or financing.However, if I know
reduce the high demand of Ozempic and the like and there would be enough
Stock for antidiabetic use, the double price would be withdrawn.According to
explains health, the exceptional measure is protected by article 94.7 of
the Law of Guarantees and Rational Use of Medicines, which indicates that
The government must make decisions about the price in situations of
shortage for reasons of general interest.

In short, the double -price system proposed
Introducing the medications of the indicated SNS has the following
goals:

• Differentiate prices.That the use regulated by the
  SNS has a more accessible price for people who truly
  They need, while the use not indicated or not funded is more
  expensive (even if you go with a recipe).
• Guarantee access.The regulated price ensures
  that patients have access to essential medicines in
  Spanish pharmacies and avoid the problem of shortage.
• Allow margins.The free price allows pharmacies to recover costs and generate benefits for the sale of medicines to other groups.

It should be noted that the health proposal has not entered into force
Not a draft, but a public consultation after project of order
ministerial.Until July 22, 2025, citizenship,
organizations and associations can send their opinions about the
Double price system for drugs raised via mail
electronicParticipation innovation.